Mark Krul has a strong track record in anticancer drug development with over 30 years of experience in the field of oncology, and a background in molecular biology and immunology. Currently, he is Chief Scientific Officer of the Oncode Accelerator Foundation. Oncode Accelerator is a public-private partnership partially funded by the Dutch National Growth Fund (350 million euros), which aims to innovate and accelerate the preclinical development of new cancer therapies by placing cancer patients at the core. Furthermore, Mark is founder and Director of Aglaia Oncology funds, co-founder of several biotech companies, and an active board member in several of Aglaia’s portfolio companies. In his early career, Mark was Program Director of the NDDO Research Foundation. He held several positions with NDDO Oncology BV (formerly the EORTC New Drug Development Office) with respect to oncology drug development strategies. Mark was Research Manager of the European Cancer Center and prior to his oncology days, he headed the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection in the Netherlands.